| Predicate |
Object |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2509-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2533-30 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-4886
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-49
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0669
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0634
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0648
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-49
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-077 |
| filingDate |
2013-02-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2021-08-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate |
2021-08-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CN-107260760-B |
| titleOfInvention |
Cell therapy for the treatment of neurodegeneration |
| abstract |
Methods for isolating and selecting a heterogeneous population of bone marrow cells, designated NCS-01, effective in treating neurodegeneration are described. For example, NCS-01 cells have been shown to treat neurodegeneration caused by ischemia. In vivo studies demonstrated that selected NCS-01 cell populations treated neurodegeneration in a standard rat Middle Cerebral Artery Occlusion (MCAO) animal model with transient or permanent complete arterial occlusion. These studies also disclose that administration of a selected NCS-01 cell population in combination with thrombolytic agents and/or mechanical clot removal methods results in a reduction in infarct volume caused by acute onset neurodegeneration when neurodegeneration is caused by ischemic stroke. The disclosed cell therapy is expected to have significant clinical impact on patients who survive a stroke. |
| priorityDate |
2013-02-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |